NCT01593527View on ClinicalTrials.gov

Canakinumab in the Treatment of Gouty Arthritis Flare(s) and Prevention of New Flares in Patients With Chronic Kidney Disease

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

September 30, 2012

Primary Completion Date

September 30, 2012

Study Completion Date

September 30, 2012

Conditions
Acute Gouty Arthritis
Interventions
DRUG

ACZ885

Canakinumab 150 mg s.c.

DRUG

Triamcinelone acetonide

Triamcinelone acetonide 40 mg i.m.

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY